Semaglutide and Knee Pain: Can GLP-1 Treatment Help You Move More Comfortably?

For someone living with knee pain, progress can mean something very practical: climbing stairs with fewer pauses, walking to the shops more comfortably or getting out of a chair with less difficulty.

These changes may matter as much as the number on the scale.

Research into semaglutide has explored this connection in people with obesity and knee osteoarthritis. The findings raise an important question: can treatment that supports weight loss also improve joint pain and everyday movement?

There is encouraging evidence, but it needs careful interpretation. Less pain does not automatically mean damaged cartilage has repaired, and a result involving one medicine and one joint condition cannot explain every ache experienced during GLP-1 treatment.

Here is what the research shows, where its limits sit and how to keep a more useful record of your own progress.

What knee osteoarthritis actually means

Osteoarthritis is a condition involving changes in the tissues of a joint, including cartilage and the underlying bone. It can cause pain, stiffness, swelling and difficulty moving.

It is often described as “wear and tear,” but that phrase can make it sound like a simple mechanical problem. Osteoarthritis affects the whole joint, and its symptoms can interfere with sleep, activity and daily life. [1]

Knee pain, however, is not automatically osteoarthritis. Injuries, tendon problems, inflammatory conditions and other causes can produce similar complaints.

Understanding the cause of your pain comes before deciding what a medication study means for you.

What the semaglutide study found

The STEP 9 trial, published in the New England Journal of Medicine in 2024, studied people with obesity and clinically and radiologically diagnosed moderate knee osteoarthritis, with at least moderate pain.

Participants received either once-weekly injectable semaglutide 2.4 mg or placebo. Both groups also received counseling on physical activity and a reduced-calorie diet.

Over 68 weeks, the semaglutide group experienced greater reductions in body weight and knee osteoarthritis pain than the placebo group. Physical function also improved more with semaglutide. [2]

This is evidence about a specific population and treatment. It should not be read as proof that any GLP-1 medication will relieve any type of joint pain.

The study was funded by Novo Nordisk. Its findings support a potential benefit in the people studied; they do not establish cartilage regeneration, a cure for osteoarthritis or that joint surgery will no longer be needed. [2]

Does this prove a direct effect on the joint?

A trial showing improvements in both weight and pain does not, by itself, tell us exactly how much of the pain improvement came through each possible pathway.

That distinction matters when reading claims that a medicine “repairs joints” or directly treats inflammation independently of weight loss.

The cautious interpretation is that semaglutide improved clinically relevant outcomes in the trial population. Establishing the precise mechanisms—and whether the same benefits apply to other groups—requires additional evidence.

For an individual patient, the more useful question may be:

“Are my symptoms and ability to move improving, and how should that affect my overall care plan?”

That question keeps the focus on an outcome you can discuss with your clinician without assuming why it happened.

Pain and function deserve separate attention

A pain score can help describe an experience, but it does not capture everything.

Consider two hypothetical people who both rate their knee pain as four out of ten.

One can walk comfortably for twenty minutes. The other avoids stairs and has difficulty standing long enough to prepare a meal.

The same number describes different practical limitations.

When discussing progress, try to distinguish:

• Pain: How uncomfortable does the knee feel?
• Function: What can you do comfortably?
• Activity: What did you actually do that day?
• Context: Did anything else change, such as physiotherapy or pain treatment?

This is a suggested way to organize observations, rather than a diagnostic scoring system. Your clinician or physiotherapist may recommend a particular questionnaire or assessment.

Why your existing joint-care plan still matters

Weight management can be part of osteoarthritis care, but it is not the entire plan.

The National Institute of Arthritis and Musculoskeletal and Skin Diseases describes treatment as a combination of approaches that may include exercise, weight management, physical therapy, medication and, in some cases, surgery.

Appropriate activity can include strengthening the muscles that support the joint, maintaining movement and building fitness. A healthcare professional can help adapt the plan to your symptoms and abilities. [3]

If you are taking semaglutide and notice improvement, discuss how to build on it safely. Avoid using a good week as a reason to abandon prescribed rehabilitation or make large changes to your activity without guidance.

Similarly, persistent pain deserves review even if weight management is going well. Your knee symptoms are an important part of your health in their own right.

How Peptimize can help organize your treatment history

Peptimize can support this conversation by keeping your medication and weight records together.

It does not diagnose osteoarthritis, assess cartilage or determine whether a joint needs treatment. Its role is to help you bring a clearer timeline to the professionals managing your care.

Keep your medication record accurate

Record the prescribed medication, dose and date you actually took it.

If your clinician changes the prescription, keep the timing clear. Include missed or delayed doses so the history reflects what happened.

This can help you explain when a change occurred without claiming that the medication caused every improvement or new symptom.

For example:

“This was when my prescription changed. Around the same period, I also started physiotherapy.”

Both details belong in the conversation.

Bring the weight trend, rather than one measurement

Peptimize’s weight history can show the course of your treatment over time.

For a joint-care appointment, ask which period your clinician wants to review. It may be useful to compare your weight history with the dates of assessments, rehabilitation or other treatment changes.

The purpose is to provide context. A weight chart alone cannot tell you what is happening inside the knee or explain why pain has changed.

Keep a separate movement record if useful

Alongside your Peptimize history, consider a short movement diary in a notebook or another format your care team recommends.

Choose a few ordinary activities that matter to you, such as:

• Walking your usual route.
• Going up or down stairs.
• Standing to cook a meal.
• Getting out of a chair.
• Completing prescribed exercises.

Describe the experience rather than trying to set a new personal record.

“Walked to the shop with one pause” is more useful than “good day.” Likewise, “stairs were uncomfortable after a longer walk” gives more context than a pain number on its own.

There is no need to repeatedly test a painful movement just to produce tracking data.

Record other treatment changes

If you start physiotherapy, change pain medication under medical guidance or receive another joint treatment, keep a record of when that happened.

Bring that information alongside your Peptimize history.

This helps avoid attributing every change to one intervention when several things may have changed at the same time.

A personal log can document a sequence. It cannot establish cause and effect.

What a useful appointment summary might look like

A short summary can make a consultation more focused:

“My Peptimize record shows my medication and weight history over the last two months. I have also kept a brief walking diary. I can now complete my usual route with fewer pauses, but stairs are still difficult. I started physiotherapy during this period. What should we review next?”

This tells your clinician:

• What information you have recorded.
• What has improved.
• What still limits you.
• What else changed.
• What you want help deciding.

You do not need a perfect record. A few consistent observations can be easier to interpret than pages of measurements collected without a clear purpose.

When knee pain needs prompt medical attention

Do not wait for a tracking pattern if you develop concerning symptoms.

Seek urgent medical advice if your knee is very painful, you cannot move it or put weight on it, or it becomes badly swollen or changes shape. A hot or red knee accompanied by fever or feeling unwell also needs urgent assessment. [4]

For pain that persists or continues to interfere with daily life, arrange a clinical review rather than assuming it will resolve as your weight changes.

Tracking is useful preparation for care. It should not postpone care.

Questions to bring to your clinician

If you have knee pain and are already receiving GLP-1 treatment, useful questions include:

1. Has the cause of my knee pain been established?
2. How relevant is the semaglutide research to my situation?
3. Which changes in movement should I record?
4. What activity or rehabilitation plan is appropriate for me?
5. When should we reassess if symptoms remain limiting?

Do not change your GLP-1 dose or start treatment solely to reproduce a trial result. Medication decisions need to account for your overall health, treatment goals and the risks and benefits of the available options.

Make everyday movement part of the conversation

A treatment review does not have to begin and end with kilograms lost.

Being able to walk more comfortably, manage stairs or participate in daily activities can be meaningful observations to share. They deserve attention alongside symptoms that remain difficult.

Peptimize can help keep the medication and weight timeline clear. Combined with a simple record of movement and guidance from your care team, that information can support a more complete discussion of your progress.

The goal is to understand how treatment fits into your life—not just how it changes a chart.

References

1. National Institute of Arthritis and Musculoskeletal and Skin Diseases. Osteoarthritis. Accessed September 28, 2026.
2. Bliddal H, Bays H, Czernichow S, et al. Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis. New England Journal of Medicine. 2024;391:1573–1583.
3. National Institute of Arthritis and Musculoskeletal and Skin Diseases. Osteoarthritis: Diagnosis, Treatment, and Steps to Take. Accessed September 28, 2026.
4. NHS. Knee pain. Accessed September 28, 2026.

For educational purposes only. Peptimize supports personal tracking and does not diagnose joint conditions or recommend medication changes.